Recent Updates
Recently added Catalysts
DARE Positive Sentiment

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Daré Bioscience has received a new NIH funding award of approximately $908,000 to support the preclinical development of DARE-PTB2, an investigational program focused on preventing preterm birth. This funding is expected to last for one year, with the possibility of an additional grant of around $1.3 million in subsequent years. The initiative aims to create a novel therapeutic approach to address this critical health issue.

Market Sentiment Analysis

POSITIVE FACTORS

  • NIH funding of approximately $908,000 supports preclinical development.
  • Potential for an additional grant of $1.3 million in future years.
  • DARE-PTB2 aims to develop a new therapeutic approach for preterm birth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~5 mo
High dilution risk
Lead asset
Lopinavir/ ritonavir
Phase 2 · Human Papilloma Virus (HPV)

Full Press Release Details

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the

Frequently Asked Questions

What is the purpose of the NIH funding for Daré?

The NIH funding supports the preclinical development of DARE-PTB2.

How much funding did Daré Bioscience receive?

Daré Bioscience received approximately $908,000 in NIH funding.

Is there potential for additional funding for DARE-PTB2?

Yes, there is potential for an additional grant of about $1.3 million.

What condition is DARE-PTB2 targeting?

DARE-PTB2 is focused on preventing preterm birth.

ShareAdd on Google
Tags: DARE Viatris Investor Conferences Healthcare Daré Bioscience NIH funding preterm birth DARE-PTB2 therapeutic approach
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$13M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
Lopinavir/ ritonavirPhase 2
Human Papilloma Virus (HPV) →